Research graph
References from Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. Local targets link to admitted publications; unresolved targets remain external evidence.
Insights into the structural and dynamical changes of spike glycoprotein mutations associated with SARS-CoV-2 host receptor binding
2020 · External reference
10.1016/j.cell.2020.02.058
10.1016/j.cell.2020.02.058 · External reference
10.1038/s41586-020-2012-7
10.1038/s41586-020-2012-7 · External reference
10.1038/s41586-020-2180-5
10.1038/s41586-020-2180-5 · External reference
10.1016/j.cell.2020.04.031
10.1016/j.cell.2020.04.031 · External reference
10.1126/science.abb2507
10.1126/science.abb2507 · External reference
10.1016/j.cell.2020.09.033
10.1016/j.cell.2020.09.033 · External reference
ACE2-independent interaction of SARS-CoV-2 spike protein to human epithelial cells can be inhibited by unfractionated heparin
2020 · External reference
10.3390/v4061011
10.3390/v4061011 · External reference
TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells
10.26508/lsa.202000786 · 2020 · External reference
10.1016/j.celrep.2020.108254
10.1016/j.celrep.2020.108254 · External reference
10.1016/j.cell.2020.02.052
10.1016/j.cell.2020.02.052 · External reference
Entry of human coronavirus NL63 into the cell
10.1128/jvi.01933-17 · 2018 · External reference
10.1128/jvi.02078-14
10.1128/jvi.02078-14 · External reference
10.1371/journal.pone.0023710
10.1371/journal.pone.0023710 · External reference
Unresolved reference
2017 · External reference
Heparan sulfate-protein interactions: therapeutic potential through structure-function insights
10.1007/s00018-004-4293-7 · 2005 · External reference
10.1101/2020.05.17.100537
10.1101/2020.05.17.100537 · External reference
10.1016/j.antiviral.2020.104873
10.1016/j.antiviral.2020.104873 · External reference
In silico investigation of phytoconstituents from Indian medicinal herb ‘Tinospora cordifolia (giloy)’ against SARS-CoV-2 (COVID-19) by molecular dynamics approach
2020 · External reference
10.1021/acsnano.0c04798
10.1021/acsnano.0c04798 · External reference
Glecaprevir and maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy
10.1042/bsr20201256 · 2020 · External reference
Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent
2020 · External reference
10.1093/glycob/cwaa042
10.1093/glycob/cwaa042 · External reference
Analysis of the SARS-CoV-2 spike protein glycan shield: implications for immune recognition
10.1038/s41598-020-71748-7 · 2020 · External reference
10.1021/acscentsci.0c01056
10.1021/acscentsci.0c01056 · External reference
COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance
10.1016/j.compbiomed.2020.103749 · 2020 · External reference
10.1038/s41565-020-0732-3
10.1038/s41565-020-0732-3 · External reference
10.1126/science.abc5902
10.1126/science.abc5902 · External reference
10.1016/j.cell.2020.05.025
10.1016/j.cell.2020.05.025 · External reference
An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors
10.1038/s41598-020-70863-9 · 2020 · External reference
10.3390/v11070596
10.3390/v11070596 · External reference
Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike s1 receptor-binding domain with heparin
10.1055/s-0040-1721319 · 2020 · External reference
10.1126/science.abd3255
10.1126/science.abd3255 · External reference
Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 Virus
10.1016/j.cell.2020.06.043 · 2020 · External reference
D614G spike mutation increases SARS CoV-2 susceptibility to neutralization
2020 · External reference
10.1101/2020.07.26.219741
10.1101/2020.07.26.219741 · External reference
10.1016/j.cell.2020.09.032
10.1016/j.cell.2020.09.032 · External reference
Unresolved reference
1999 · External reference
Unresolved reference
External reference
10.1016/j.molcel.2020.04.022
10.1016/j.molcel.2020.04.022 · External reference
A human monoclonal antibody blocking SARS-CoV-2 infection
10.1038/s41467-020-16256-y · 2020 · External reference
10.1038/s41423-020-0426-7
10.1038/s41423-020-0426-7 · External reference
10.1126/science.abb7269
10.1126/science.abb7269 · External reference
10.1126/science.abc2241
10.1126/science.abc2241 · External reference
10.1038/s41586-020-2380-z
10.1038/s41586-020-2380-z · External reference
10.1126/science.abc0870
10.1126/science.abc0870 · External reference
10.1126/science.abd0831
10.1126/science.abd0831 · External reference
10.1126/science.abc6952
10.1126/science.abc6952 · External reference
10.1101/2020.06.30.178897
10.1101/2020.06.30.178897 · External reference
Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro
10.1038/s41421-020-00192-8 · 2020 · External reference
10.5694/mja2.50569
10.5694/mja2.50569 · External reference
Unresolved reference
External reference
10.1101/2020.12.21.20248640
10.1101/2020.12.21.20248640 · External reference
10.1093/nar/gky427
10.1093/nar/gky427 · External reference
10.1016/j.cell.2020.03.045
10.1016/j.cell.2020.03.045 · External reference
10.1002/jcc.20084
10.1002/jcc.20084 · External reference
10.1002/jcc.20945
10.1002/jcc.20945 · External reference
10.1021/acs.jctc.5b00935
10.1021/acs.jctc.5b00935 · External reference
10.1093/glycob/cwz003
10.1093/glycob/cwz003 · External reference
10.1063/1.445869
10.1063/1.445869 · External reference
10.1016/0021-9991(77)90098-5
10.1016/0021-9991(77)90098-5 · External reference
10.1016/j.softx.2015.06.001 · Admitted local publication
Unresolved reference
External reference
10.1002/jcc.23354
10.1002/jcc.23354 · External reference
10.1016/0263-7855(96)00018-5
10.1016/0263-7855(96)00018-5 · External reference
10.1002/gch2.1018
10.1002/gch2.1018 · External reference
10.1021/acs.jcim.0c00373
10.1021/acs.jcim.0c00373 · External reference
Unresolved reference
External reference
10.1021/ci500115j
10.1021/ci500115j · External reference
10.1002/pro.3943
10.1002/pro.3943 · External reference
The nature of the conserved basic amino acid sequences found among 437 heparin binding proteins determined by network analysis
10.1039/c6mb00857g · 2017 · External reference
10.25080/majora-629e541a-00e
10.25080/majora-629e541a-00e · External reference
10.1021/ci500020m
10.1021/ci500020m · External reference
The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities
10.1517/17460441.2015.1032936 · 2015 · External reference
10.1093/nar/gkh381
10.1093/nar/gkh381 · External reference
10.4208/cicp.300611.201011s
10.4208/cicp.300611.201011s · External reference
DelPhi web server v2: incorporating atomic-style geometrical figures into the computational protocol
10.1093/bioinformatics/bts200 · 2012 · External reference
10.1002/pro.3235
10.1002/pro.3235 · External reference
10.1038/s41586-020-2169-0
10.1038/s41586-020-2169-0 · External reference
Recurrent mutations in SARS-CoV-2 genomes isolated from mink point to rapid host-adaptation
2020 · External reference
10.1021/acs.jmedchem.6b00399
10.1021/acs.jmedchem.6b00399 · External reference
10.1021/acs.jpcb.0c04553
10.1021/acs.jpcb.0c04553 · External reference
Flexible, functional, and familiar: characteristics of SARS-CoV-2 spike protein evolution
10.3389/fmicb.2020.02112 · 2020 · External reference
The structural basis of accelerated host cell entry by SARS-CoV-2
2020 · External reference
Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein
10.1016/j.virusres.2020.198058 · 2020 · External reference
10.1002/jcc.21787
10.1002/jcc.21787 · External reference
Heterogeneity of heparan sulfates in human lung
10.1165/rcmb.2003-0198oc · 2004 · External reference
Heparan sulfate in the developing, healthy, and injured lung
10.1165/rcmb.2016-0043tr · 2016 · External reference
Molecular Interactions between Complement Factor H and Its Heparin and Heparan Sulfate Ligands
10.3389/fimmu.2014.00126 · 2014 · External reference
Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition
10.4103/0976-9668.127282 · 2014 · External reference
Structural glycobiology of heparin dynamics on the exosite 2 of coagulation cascade proteases: implications for glycosaminoglycans antithrombotic activity
10.1093/glycob/cwt095 · 2013 · External reference
Unresolved reference
2011 · External reference
Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity
10.1006/abbi.1997.9973 · 1997 · External reference
10.1056/nejmc2031364
10.1056/nejmc2031364 · External reference
Unresolved reference
External reference
10.1101/2020.05.10.087288
10.1101/2020.05.10.087288 · External reference
10.1038/nprot.2007.321
10.1038/nprot.2007.321 · External reference
Unfractionated heparin inhibits live wild-type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations
2020 · External reference
10.1016/j.antiviral.2005.08.006
10.1016/j.antiviral.2005.08.006 · External reference
10.1093/bioinformatics/btp033
10.1093/bioinformatics/btp033 · External reference
